Fraunhofer Institute for Cell Therapy and Immunology IZI

Fraunhofer Life Science Symposium 2017 – Final scientific program online!

November 8–9, 2017 | Fraunhofer IZI Leipzig, Germany

more info

We transfer biomedical research into the clinic.

The Fraunhofer Institute for Cell Therapy and Immunology IZI investigates and develops solutions to specific problems at the interfaces of medicine, life sciences and engineering.

One of the institute's main tasks is to conduct contract research for companies, hospitals, diagnostic laboratories and research institutes operating in the field of biotechnology, pharmaceuticals and medical engineering.

The Fraunhofer IZI develops, optimizes and validates methods, materials and products for the business units Cell and Gene Therapy, Drugs, Diagnostics and Biosystems Technology.

Its areas of competence lie in cell biology, immunology, drug biochemistry, biomarker, bioanalytics and bioproduction as well as process development and automation.

In these areas, research specifically focusses on the indications oncology, neuropathology, autoimmune and inflammatory diseases as well as infectious diseases and regenerative medicine.

The institute works in close cooperation with hospital institutions and performs quality tests besides carrying out the GMP-compliant manufacture of clinical test samples. Furthermore, it helps partners obtain manufacturing licenses and permits.

Business units

Jobs / career





Press information / 7.9.2017

Specialist group Image Analysis of Cell Function successfully evaluated

On 12 August 2014, the Fraunhofer Institute for Cell Therapy and Immunology and Leipzig University of Applied Sciences (HTWK Leipzig) got the ball rolling on a joint specialist group focused on the “Image Analysis of Cell Function”. The group was evaluated and its future viability assessed on 4 August 2017, following a three-year start-up phase. The evaluation committee, made up of representatives from science, business and politics, attested to the outstanding work completed by the team, which is headed up by Professor Ulf-Dietrich Braumann, during this early phase and unanimously recommended that the specialist group be continued. The group's high level of commitment to the teaching and training of young scientists also received a special mention.

Press information / 29.8.2017

Researchers describe novel antibody as potential active agent against Alzheimer's

Antibodies against Alzheimer’s disease: researchers from Martin Luther University of Halle-Wittenberg (MLU), the Fraunhofer Institute for Cell Therapy and Immunology IZI and Halle-based company Probiodrug AG have succeeded in developing antibodies as potential active agents against the disease. At the same time, they have been able to describe the structure of a harmful form of the peptide associated with Alzheimer’s in detail for the first time. The research units are presenting their findings in the globally renowned “Journal of Biological Chemistry”.


Press information / 31.7.2017

Fraunhofer Institute for Cell Therapy and Immunology sets up research unit at Monash University in Melbourne, Australia


Press information / 20.7.2017

Recognising dyslexia in time: Foundations laid for future early test

Five years of common research has made it possible: An early test which recognises widespread dyslexia in time–and would therefore spare about five per cent of children a long path of suffering. Scientists at the Max Planck Institute for Human Cognitive and Brain Sciences and the Fraunhofer Institute for Cell Therapy and Immunology (IZI) have succeeded in laying the foundations for a test which, with the help of brain activity and gene analyses, could predict whether a child could be affected by this disorder. The conclusion of their research project LEGASCREEN offers an opportunity to reflect on current and future dyslexia diagnosis.the Bill & Melinda Gates Foundation.


Fraunhofer IZI


Perlickstraße 1
04103 Leipzig

Phone +49 341 35536-1000
Fax +49 341 35536-8-1000



Social Media